Respiratory distress syndrome is a major cause of morbidity in preterm infants. Non-invasive respiratory support with nasal continuous positive airway pressure (nCPAP) or high-flow nasal cannula (HFNC) is commonly used to avoid intubation.
This prospective randomized parallel-group trial will compare treatment failure rates within the first 72 hours between preterm infants receiving nCPAP and those receiving HFNC as initial respiratory support.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Preterm infants with gestational age 28 to 36 weeks and 6 days
Clinical diagnosis of respiratory distress syndrome
Spontaneous breathing without immediate need for invasive mechanical ventilation
Requirement for non-invasive respiratory support
Written informed consent from parent or legal guardian
You may not be if
\- Infants requiring immediate endotracheal intubation and mechanical ventilation
Major congenital anomalies affecting the respiratory or cardiovascular systems
Congenital diaphragmatic hernia
Significant congenital heart disease
Severe perinatal asphyxia requiring prolonged resuscitation
Severe hemodynamic instability
Prolonged mechanical ventilation before enrollment